Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amarin Corp ADR (AMRN)

Amarin Corp ADR (AMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amarin Corp ADR Iconic Offices The Greenway Block C Ardilaun Court 112 - 114 Street DUBLIN L2 Dublin 2 IRL

www.amarincorp.com Employees: 275 P: 353-1669-9020

Description:

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels.

Key Statistics

Overview:

Market Capitalization, $K 244,309
Enterprise Value, $K 44,529
Shares Outstanding, K 410,672
Annual Sales, $ 306,910 K
Annual Net Income, $ -59,110 K
Last Quarter Sales, $ 67,490 K
Last Quarter Net Income, $ 1,520 K
EBIT, $ -40,390 K
EBITDA, $ -37,420 K
60-Month Beta 1.92
% of Insider Shareholders 1.96%
% of Institutional Shareholders 22.25%
Float, K 402,623
% Float 98.04%
Short Volume Ratio 0.29

Growth:

1-Year Return -30.47%
3-Year Return -88.47%
5-Year Return -96.31%
5-Year Revenue Growth 33.90%
5-Year Earnings Growth 61.54%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.01 on 07/31/24
Next Earnings Date 11/06/24
Earnings Per Share ttm -0.08
EPS Growth vs. Prev Qtr 100.00%
EPS Growth vs. Prev Year 100.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 02/19/08

AMRN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -6.09%
Return-on-Assets % -4.11%
Profit Margin % -19.26%
Debt/Equity 0.00
Price/Sales 0.77
Price/Cash Flow N/A
Price/Book 0.44
Book Value/Share 1.34
Interest Coverage -5,366.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar